Related Experiment Video
Updated: Jun 27, 2026

09:47
DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Enhancing Early Detection of Alzheimer's Disease: An Ensemble Model for Multi-Domain Cognitive Assessment Using Voice
Shinwoo Ham1, Donghun Min1,2, Hyo Jin Jon1
1Voinosis Inc., Seoul 05029, Republic of Korea.
Sensors (Basel, Switzerland)
|June 26, 2026
Summary
Early Alzheimer's disease (AD) detection is improved with a new non-invasive digital biomarker framework. This multi-modal approach using voice and video data offers a scalable and accurate solution for accessible AD screening.
Area of Science:
- Neuroscience
- Biomarkers
- Digital Health
Background:
- Early Alzheimer's disease (AD) detection is critical but faces challenges with invasive and costly traditional methods.
- There is a significant need for accessible, non-invasive biomarkers for precise AD screening.
- Cognitive impairments in AD affect domains like language, memory, and attention.
Purpose of the Study:
- To develop and validate a multi-modal digital biomarker framework for accurate, non-invasive Alzheimer's disease detection.
- To assess the framework's performance across multiple cognitive domains using voice and video data.
- To enhance screening accessibility and real-world applicability.
Main Methods:
- A multi-modal digital biomarker framework was proposed, analyzing voice and video data.
- The framework evaluated cognitive functions including language, working memory, and visuospatial attention.
- An ensemble strategy was employed to integrate results from individual cognitive tasks.
Main Results:
- Individual cognitive tasks showed F1-scores from 69.23% to 77.78% and sensitivities from 69.23% to 80.77%.
- The ensemble strategy significantly improved detection performance.
- The final framework achieved an F1-score of 83.64% and a sensitivity of 88.46% in a dataset of 128 participants (51 AD, 77 HCs).
Conclusions:
- The proposed multi-modal digital biomarker framework offers a highly accurate solution for non-invasive Alzheimer's disease screening.
- Ensemble methods enhance the framework's detection capabilities, improving scalability and practicality.
- This digital approach represents a significant advancement in accessible and early AD detection.
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.